These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 31651200)

  • 41. Urinary Exosomal and cell-free DNA Detects Somatic Mutation and Copy Number Alteration in Urothelial Carcinoma of Bladder.
    Lee DH; Yoon H; Park S; Kim JS; Ahn YH; Kwon K; Lee D; Kim KH
    Sci Rep; 2018 Oct; 8(1):14707. PubMed ID: 30279572
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Liquid Biopsy: Approaches to Dynamic Genotyping in Cancer.
    von Bubnoff N
    Oncol Res Treat; 2017; 40(7-8):409-416. PubMed ID: 28693026
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Liquid Biopsy: Emergence of an Alternative Cancer Detection Method.
    Law EW; Settell ML; Kurani SS; Eckert EC; Liu MC; Greenberg-Worisek AJ
    Clin Transl Sci; 2020 Sep; 13(5):845-847. PubMed ID: 32233063
    [No Abstract]   [Full Text] [Related]  

  • 44. Monitoring Melanoma Using Circulating Free DNA.
    Diefenbach RJ; Lee JH; Rizos H
    Am J Clin Dermatol; 2019 Feb; 20(1):1-12. PubMed ID: 30374893
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Liquid Biopsy Biomarkers in Bladder Cancer: A Current Need for Patient Diagnosis and Monitoring.
    Lodewijk I; Dueñas M; Rubio C; Munera-Maravilla E; Segovia C; Bernardini A; Teijeira A; Paramio JM; Suárez-Cabrera C
    Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30149597
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Liquid Biopsy beyond Circulating Tumor Cells and Cell-Free DNA.
    Junqueira-Neto S; Batista IA; Costa JL; Melo SA
    Acta Cytol; 2019; 63(6):479-488. PubMed ID: 30783027
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Honing the Hunt: A Comprehensive Review of Cell-free Tumor DNA to Predict Neoadjuvant Therapy Efficacy in Bladder Cancer.
    Suartz CV; Martinez LM; Cordeiro MD; Botelho LAA; Gallutti FP; Mota JM; Leite KRM; Toren P; Nahas WC; Ribeiro-Filho LA
    Clin Genitourin Cancer; 2024 Jun; 22(3):102087. PubMed ID: 38688207
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Promises and Pitfalls of Using Liquid Biopsy for Precision Medicine.
    Rossi G; Ignatiadis M
    Cancer Res; 2019 Jun; 79(11):2798-2804. PubMed ID: 31109952
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Circulating tumor DNA in advanced solid tumors: Clinical relevance and future directions.
    Cheng ML; Pectasides E; Hanna GJ; Parsons HA; Choudhury AD; Oxnard GR
    CA Cancer J Clin; 2021 Mar; 71(2):176-190. PubMed ID: 33165928
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Assessment of circulating tumor DNA in pediatric solid tumors: The promise of liquid biopsies.
    Abbou SD; Shulman DS; DuBois SG; Crompton BD
    Pediatr Blood Cancer; 2019 May; 66(5):e27595. PubMed ID: 30614191
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Perspectives of the Application of Liquid Biopsy in Colorectal Cancer.
    Ding Y; Li W; Wang K; Xu C; Hao M; Ding L
    Biomed Res Int; 2020; 2020():6843180. PubMed ID: 32258135
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Early detection and monitoring of cancer in liquid biopsy: advances and challenges.
    Xue VW; Wong CSC; Cho WCS
    Expert Rev Mol Diagn; 2019 Apr; 19(4):273-276. PubMed ID: 30760042
    [No Abstract]   [Full Text] [Related]  

  • 53. Circulating and urinary tumour DNA in urothelial carcinoma - upper tract, lower tract and metastatic disease.
    Rose KM; Huelster HL; Meeks JJ; Faltas BM; Sonpavde GP; Lerner SP; Ross JS; Spiess PE; Grass GD; Jain RK; Kamat AM; Vosoughi A; Wang L; Wang X; Li R
    Nat Rev Urol; 2023 Jul; 20(7):406-419. PubMed ID: 36977797
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Multimodal analysis of cell-free DNA whole-genome sequencing for pediatric cancers with low mutational burden.
    Peneder P; Stütz AM; Surdez D; Krumbholz M; Semper S; Chicard M; Sheffield NC; Pierron G; Lapouble E; Tötzl M; Ergüner B; Barreca D; Rendeiro AF; Agaimy A; Boztug H; Engstler G; Dworzak M; Bernkopf M; Taschner-Mandl S; Ambros IM; Myklebost O; Marec-Bérard P; Burchill SA; Brennan B; Strauss SJ; Whelan J; Schleiermacher G; Schaefer C; Dirksen U; Hutter C; Boye K; Ambros PF; Delattre O; Metzler M; Bock C; Tomazou EM
    Nat Commun; 2021 May; 12(1):3230. PubMed ID: 34050156
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Liquid biopsy in non-small cell lung cancer: a key role in the future of personalized medicine?
    Pi C; Zhang MF; Peng XX; Zhang YC; Xu CR; Zhou Q
    Expert Rev Mol Diagn; 2017 Dec; 17(12):1089-1096. PubMed ID: 29057681
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Beyond Standard Practice in Liquid Biopsy: Selective Venous Sampling.
    Damascelli B; Tichà V; Repetti E; Dorji T
    J Vasc Interv Radiol; 2021 May; 32(5):668-671. PubMed ID: 33621662
    [TBL] [Abstract][Full Text] [Related]  

  • 57. ctDNA: Moving toward Clinical Utility.
    Cancer Discov; 2022 Aug; 12(8):OF4. PubMed ID: 35671334
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Application of liquid biopsy in precision medicine: opportunities and challenges.
    Wang J; Chang S; Li G; Sun Y
    Front Med; 2017 Dec; 11(4):522-527. PubMed ID: 28744793
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Circulating Tumor DNA: A Step into the Future of Cancer Management.
    Fernandes Marques J; Pereira Reis J; Fernandes G; Hespanhol V; Machado JC; Costa JL
    Acta Cytol; 2019; 63(6):456-465. PubMed ID: 30852572
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Liquid Biopsy in Breast Cancer: A Focused Review.
    Tay TKY; Tan PH
    Arch Pathol Lab Med; 2021 Jun; 145(6):678-686. PubMed ID: 32045277
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.